A000520 Stock Overview
Engages in the manufacture and sale of indispensable medicines in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Samil Pharmaceutical Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩13,900.00 |
| 52 Week High | ₩19,500.00 |
| 52 Week Low | ₩7,070.00 |
| Beta | 0.42 |
| 1 Month Change | 20.24% |
| 3 Month Change | -12.03% |
| 1 Year Change | 89.12% |
| 3 Year Change | 82.68% |
| 5 Year Change | 52.14% |
| Change since IPO | 1,059.61% |
Recent News & Updates
Some Samil Pharmaceutical Co.,Ltd (KRX:000520) Shareholders Look For Exit As Shares Take 27% Pounding
Nov 18
Optimistic Investors Push Samil Pharmaceutical Co.,Ltd (KRX:000520) Shares Up 29% But Growth Is Lacking
Sep 13We Think Samil PharmaceuticalLtd (KRX:000520) Is Taking Some Risk With Its Debt
Sep 11Recent updates
Some Samil Pharmaceutical Co.,Ltd (KRX:000520) Shareholders Look For Exit As Shares Take 27% Pounding
Nov 18Optimistic Investors Push Samil Pharmaceutical Co.,Ltd (KRX:000520) Shares Up 29% But Growth Is Lacking
Sep 13We Think Samil PharmaceuticalLtd (KRX:000520) Is Taking Some Risk With Its Debt
Sep 11Investor Optimism Abounds Samil Pharmaceutical Co.,Ltd (KRX:000520) But Growth Is Lacking
Jul 29Does Samil PharmaceuticalLtd (KRX:000520) Have A Healthy Balance Sheet?
May 24There's Reason For Concern Over Samil Pharmaceutical Co.,Ltd's (KRX:000520) Massive 29% Price Jump
Mar 30Samil PharmaceuticalLtd's (KRX:000520) Earnings Are Of Questionable Quality
Mar 21Here's Why Samil PharmaceuticalLtd (KRX:000520) Has A Meaningful Debt Burden
Apr 01Samil PharmaceuticalLtd (KRX:000520) Has Gifted Shareholders With A Fantastic 141% Total Return On Their Investment
Mar 11Are Dividend Investors Getting More Than They Bargained For With Samil Pharmaceutical Co.,Ltd's (KRX:000520) Dividend?
Feb 15
Should You Be Concerned About Samil Pharmaceutical Co.,Ltd's (KRX:000520) ROE?
Jan 20Why It Might Not Make Sense To Buy Samil Pharmaceutical Co.,Ltd (KRX:000520) For Its Upcoming Dividend
Dec 24Samil PharmaceuticalLtd (KRX:000520) Has Gifted Shareholders With A Fantastic 221% Total Return On Their Investment
Dec 09What Is The Ownership Structure Like For Samil Pharmaceutical Co.,Ltd (KRX:000520)?
Nov 18Shareholder Returns
| A000520 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 8.9% | 1.4% | -0.8% |
| 1Y | 89.1% | -0.07% | -10.1% |
Return vs Industry: A000520 exceeded the KR Pharmaceuticals industry which returned -3.3% over the past year.
Return vs Market: A000520 exceeded the KR Market which returned -10.9% over the past year.
Price Volatility
| A000520 volatility | |
|---|---|
| A000520 Average Weekly Movement | 10.3% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.8% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A000520's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A000520's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1947 | 585 | Kang Huh | www.samil-pharm.com |
Samil Pharmaceutical Co.,Ltd engages in the manufacture and sale of indispensable medicines in South Korea. It offers hepatic, gastrointestinal, vasodilator, antithrombotic, respiratory, skeletal muscle relaxants, circulatory, neurological, antibiotics, metabolic, antihistamines, immunosuppressive, hormone, anti-tumor, urinary, and ophthalmic drugs, as well as antipyretic, analgesic, and anti-inflammatory agents. The company also provides OTC products and sanitary aids.
Samil Pharmaceutical Co.,Ltd Fundamentals Summary
| A000520 fundamental statistics | |
|---|---|
| Market cap | ₩295.09b |
| Earnings (TTM) | -₩1.17b |
| Revenue (TTM) | ₩212.42b |
1.4x
P/S Ratio-251.3x
P/E RatioIs A000520 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A000520 income statement (TTM) | |
|---|---|
| Revenue | ₩212.42b |
| Cost of Revenue | ₩132.07b |
| Gross Profit | ₩80.36b |
| Other Expenses | ₩81.53b |
| Earnings | -₩1.17b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -55.31 |
| Gross Margin | 37.83% |
| Net Profit Margin | -0.55% |
| Debt/Equity Ratio | 82.2% |
How did A000520 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 06:41 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Samil Pharmaceutical Co.,Ltd is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sun-Jae Heo | SK Securities Co., Ltd. |